Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · IEX Real-Time Price · USD
9.32
-0.01 (-0.11%)
At close: Jul 19, 2024, 4:00 PM
9.40
+0.08 (0.86%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease.
Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Dr. Carole S. Ben-Maimon M.D. |
Contact Details
Address: Three Bala Plaza East. Suite 506 Bala Cynwyd, Pennsylvania 19004 United States | |
| Phone | 844-511-9056 |
| Website | larimartx.com |
Stock Details
| Ticker Symbol | LRMR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001374690 |
| CUSIP Number | 517125100 |
| ISIN Number | US5171251003 |
| Employer ID | 20-3857670 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carole S. Ben-Maimon M.D. | Chief Executive Officer, President and Director |
| Michael Celano CPA | Secretary and Chief Financial Officer |
| John Berman | Vice President of Finance and Administration |
| Jennifer Spokes Johansson | Vice President of Legal and Compliance |
| Dr. Russell G. Clayton Sr., D.O | Chief Medical Officer |
| Dr. Gopi Shankar M.B.A., Ph.D. | Chief Development Officer |
| Francis Michael Conway CPA | Vice President and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 10, 2024 | 8-K | Current Report |
| May 31, 2024 | 8-K | Current Report |
| May 30, 2024 | 8-K | Current Report |
| May 24, 2024 | EFFECT | Notice of Effectiveness |
| May 20, 2024 | 8-K | Current Report |
| May 16, 2024 | UPLOAD | Filing |
| May 9, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Apr 29, 2024 | ARS | Filing |